PortalPublikationenEffects of diadenosine polyphosphates on renal function and ...

Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats

Standard

Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats. / Hohage, H; Reinhardt, C; Borucki, U; Enck, G; Schlüter, H; Schlatter, E; Zidek, W.

in: J AM SOC NEPHROL, Jahrgang 7, Nr. 8, 08.1996, S. 1216-22.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hohage, H, Reinhardt, C, Borucki, U, Enck, G, Schlüter, H, Schlatter, E & Zidek, W 1996, 'Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats', J AM SOC NEPHROL, Jg. 7, Nr. 8, S. 1216-22.

APA

Hohage, H., Reinhardt, C., Borucki, U., Enck, G., Schlüter, H., Schlatter, E., & Zidek, W. (1996). Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats. J AM SOC NEPHROL, 7(8), 1216-22.

Vancouver

Hohage H, Reinhardt C, Borucki U, Enck G, Schlüter H, Schlatter E et al. Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats. J AM SOC NEPHROL. 1996 Aug;7(8):1216-22.

Bibtex

@article{1aec12c39e2f494b9691bb601cc64428,
title = "Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats",
abstract = "In this study, the effects of diadenosine polyphosphates on kidney function were examined. Intravenous application of diadenosine hexaphosphate (AP6A) led to a significant threefold increase in both urine flow (from 2.45 +/- 0.2 to 13.8 +/- 0.74 microL/min per 100 g body wt (P < 0.05)) and Na+ excretion (from 0.41 +/- 0.12 to 1.52 +/- 0.28 mumol/min per 100 g body wt at a dose of 1.0 mg/kg body wt). In contrast, diadenosine triphosphate dose-dependently reduced urine flow (from 3.74 +/- 0.3 to 2.57 +/- 0.1 microL/min per 100 g body wt (P < 0.05)) and Na+ excretion (from 0.45 +/- 0.1 to 0.13 +/- 0.1 mumol/min per 100 g body wt at a dose of 1.0 mg/kg body wt). ATP and the P2y purinoceptor agonist gamma-S-ATP did not significantly modulate urine flow and Na+ excretion. alpha, beta-methylene-ATP, a P2x purinoceptor agonist, significantly increased urine flow from 1.74 +/- 0.5 to 4.07 +/- 1.51 microL/min per 100 g body wt, whereas Na+ excretion was unaffected. The effects were independent of alterations in GFR. Pretreatment with indomethacin (2.0 mg/kg body wt iv) completely abolished the effects of AP6A on urine flow and Na+ excretion. Similarly, pretreatment with the endothelin antagonist bosentan abolished the effects of AP6A on both urine flow and Na+ excretion, whereas suramin had no effects on the AP6A-induced increase in urine flow. In conclusion, diadenosine polyphosphates exert specific actions on urine flow and Na+ excretion that are different from the effects of ATP. AP6A may partially influence renal function by stimulating prostaglandin and endothelin release.",
keywords = "Anesthesia, Animals, Blood Pressure, Bosentan, Cyclooxygenase Inhibitors, Dinucleoside Phosphates, Diuresis, Endothelins, Enzyme Inhibitors, Glomerular Filtration Rate, Indomethacin, Kidney, Male, NG-Nitroarginine Methyl Ester, Natriuresis, Nitric Oxide Synthase, Prostaglandins, Rats, Rats, Wistar, Sulfonamides, Vasoconstrictor Agents, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't",
author = "H Hohage and C Reinhardt and U Borucki and G Enck and H Schl{\"u}ter and E Schlatter and W Zidek",
year = "1996",
month = aug,
language = "English",
volume = "7",
pages = "1216--22",
journal = "J AM SOC NEPHROL",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

RIS

TY - JOUR

T1 - Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats

AU - Hohage, H

AU - Reinhardt, C

AU - Borucki, U

AU - Enck, G

AU - Schlüter, H

AU - Schlatter, E

AU - Zidek, W

PY - 1996/8

Y1 - 1996/8

N2 - In this study, the effects of diadenosine polyphosphates on kidney function were examined. Intravenous application of diadenosine hexaphosphate (AP6A) led to a significant threefold increase in both urine flow (from 2.45 +/- 0.2 to 13.8 +/- 0.74 microL/min per 100 g body wt (P < 0.05)) and Na+ excretion (from 0.41 +/- 0.12 to 1.52 +/- 0.28 mumol/min per 100 g body wt at a dose of 1.0 mg/kg body wt). In contrast, diadenosine triphosphate dose-dependently reduced urine flow (from 3.74 +/- 0.3 to 2.57 +/- 0.1 microL/min per 100 g body wt (P < 0.05)) and Na+ excretion (from 0.45 +/- 0.1 to 0.13 +/- 0.1 mumol/min per 100 g body wt at a dose of 1.0 mg/kg body wt). ATP and the P2y purinoceptor agonist gamma-S-ATP did not significantly modulate urine flow and Na+ excretion. alpha, beta-methylene-ATP, a P2x purinoceptor agonist, significantly increased urine flow from 1.74 +/- 0.5 to 4.07 +/- 1.51 microL/min per 100 g body wt, whereas Na+ excretion was unaffected. The effects were independent of alterations in GFR. Pretreatment with indomethacin (2.0 mg/kg body wt iv) completely abolished the effects of AP6A on urine flow and Na+ excretion. Similarly, pretreatment with the endothelin antagonist bosentan abolished the effects of AP6A on both urine flow and Na+ excretion, whereas suramin had no effects on the AP6A-induced increase in urine flow. In conclusion, diadenosine polyphosphates exert specific actions on urine flow and Na+ excretion that are different from the effects of ATP. AP6A may partially influence renal function by stimulating prostaglandin and endothelin release.

AB - In this study, the effects of diadenosine polyphosphates on kidney function were examined. Intravenous application of diadenosine hexaphosphate (AP6A) led to a significant threefold increase in both urine flow (from 2.45 +/- 0.2 to 13.8 +/- 0.74 microL/min per 100 g body wt (P < 0.05)) and Na+ excretion (from 0.41 +/- 0.12 to 1.52 +/- 0.28 mumol/min per 100 g body wt at a dose of 1.0 mg/kg body wt). In contrast, diadenosine triphosphate dose-dependently reduced urine flow (from 3.74 +/- 0.3 to 2.57 +/- 0.1 microL/min per 100 g body wt (P < 0.05)) and Na+ excretion (from 0.45 +/- 0.1 to 0.13 +/- 0.1 mumol/min per 100 g body wt at a dose of 1.0 mg/kg body wt). ATP and the P2y purinoceptor agonist gamma-S-ATP did not significantly modulate urine flow and Na+ excretion. alpha, beta-methylene-ATP, a P2x purinoceptor agonist, significantly increased urine flow from 1.74 +/- 0.5 to 4.07 +/- 1.51 microL/min per 100 g body wt, whereas Na+ excretion was unaffected. The effects were independent of alterations in GFR. Pretreatment with indomethacin (2.0 mg/kg body wt iv) completely abolished the effects of AP6A on urine flow and Na+ excretion. Similarly, pretreatment with the endothelin antagonist bosentan abolished the effects of AP6A on both urine flow and Na+ excretion, whereas suramin had no effects on the AP6A-induced increase in urine flow. In conclusion, diadenosine polyphosphates exert specific actions on urine flow and Na+ excretion that are different from the effects of ATP. AP6A may partially influence renal function by stimulating prostaglandin and endothelin release.

KW - Anesthesia

KW - Animals

KW - Blood Pressure

KW - Bosentan

KW - Cyclooxygenase Inhibitors

KW - Dinucleoside Phosphates

KW - Diuresis

KW - Endothelins

KW - Enzyme Inhibitors

KW - Glomerular Filtration Rate

KW - Indomethacin

KW - Kidney

KW - Male

KW - NG-Nitroarginine Methyl Ester

KW - Natriuresis

KW - Nitric Oxide Synthase

KW - Prostaglandins

KW - Rats

KW - Rats, Wistar

KW - Sulfonamides

KW - Vasoconstrictor Agents

KW - Comparative Study

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - SCORING: Journal article

C2 - 8866415

VL - 7

SP - 1216

EP - 1222

JO - J AM SOC NEPHROL

JF - J AM SOC NEPHROL

SN - 1046-6673

IS - 8

ER -